Industry analysts say a takeover of Serono by GlaxoSmithKline would significantly boost GSK's presence in the area of biological medicines, which GSK was aiming for last year with the creation of its Biopharmaceutical Center of Excellence for Drug Discovery. Also, since both companies are trying to develop multiple sclerosis treatments, the acquisition would give GSK two shots at success in a potentially lucrative business area.

Full Story:

Related Summaries